AMRX
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ: AMRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$12.80
+0.51% today
Updated 2026-04-29
Market cap
$4.08B
P/E ratio
58.18
P/S ratio
1.35x
EPS (TTM)
$0.22
Dividend yield
—
52W range
$7 – $15
Volume
1.9M
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $785.62M | $866.28M | $1.02B | $1.03B | $1.66B | $1.63B | $1.99B | $2.09B | $2.21B | $2.39B | $2.79B | $3.02B |
| Revenue growth (YoY) | — | +10.3% | +17.5% | +1.5% | +60.9% | -2.2% | +22.5% | +5.1% | +5.7% | +8.2% | +16.7% | +8.0% |
| Cost of revenue | $335.99M | $367.05M | $420.77M | $507.48M | $946.59M | $1.27B | $1.36B | $1.32B | $1.42B | $1.53B | $1.77B | $1.88B |
| Gross profit | $449.63M | $499.23M | $597.46M | $526.18M | $716.40M | $353.00M | $628.39M | $768.97M | $791.46M | $863.87M | $1.02B | $1.14B |
| Gross margin | 57.2% | 57.6% | 58.7% | 50.9% | 43.1% | 21.7% | 31.5% | 36.7% | 35.8% | 36.1% | 36.5% | 37.6% |
| R&D | $106.73M | $136.87M | $204.75M | $191.94M | $210.45M | $202.29M | $190.59M | $209.56M | $208.66M | $194.75M | $190.71M | $186.18M |
| SG&A | $84.61M | $201.29M | $118.76M | $109.05M | $230.44M | $289.60M | $326.73M | $365.70M | $382.90M | $417.27M | $442.04M | $526.83M |
| Operating income | $222.94M | $227.23M | $284.88M | $245.10M | $-19.67M | $-248.68M | $91.16M | $152.72M | $-94.93M | $204.37M | $249.33M | $423.09M |
| Operating margin | 28.4% | 26.2% | 28.0% | 23.7% | -1.2% | -15.3% | 4.6% | 7.3% | -4.3% | 8.5% | 8.9% | 14.0% |
| EBITDA | $243.28M | $252.68M | $306.97M | $271.13M | $-19.67M | $155.20M | $345.61M | $401.10M | $440.21M | $500.78M | $439.77M | $603.87M |
| EBITDA margin | 31.0% | 29.2% | 30.1% | 26.2% | -1.2% | 9.5% | 17.3% | 19.2% | 19.9% | 20.9% | 15.7% | 20.0% |
| EBIT | $222.94M | $227.23M | $273.95M | $225.19M | $-157.08M | $-52.04M | $110.22M | $167.69M | $200.03M | $271.38M | $203.58M | $380.30M |
| Interest expense | $0.00 | $0.00 | $55.28M | $71.06M | $143.57M | $168.21M | $146.00M | $136.32M | $158.38M | $210.63M | $258.60M | $241.09M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $176.93M | $169.45M | $207.38M | $167.65M | $-169.73M | $-361.92M | $91.06M | $10.62M | $-129.99M | $-83.99M | $-116.89M | $72.06M |
| Net income growth (YoY) | — | -4.2% | +22.4% | -19.2% | -201.2% | -113.2% | +125.2% | -88.3% | -1323.5% | +35.4% | -39.2% | +161.6% |
| Profit margin | 22.5% | 19.6% | 20.4% | 16.2% | -10.2% | -22.3% | 4.6% | 0.5% | -5.9% | -3.5% | -4.2% | 2.4% |